Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB092 in mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease
2017-002901-37Phase 2Completed
- Sponsor
- Biogen
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) and mild cognitive impairment due to Alzheimer's disease comparing BIIB092 with Placebo (2 arms). Primary endpoint: Percentage of participants with adverse events and serious adverse events. Started Dec 2017; status: completed.
02
Drugs
gosuranemab
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on 2017-002901-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002901-37.